Log in to your Inderes Free account to see all free content on this page.
Medivir
0.38 SEK
+0.92 %
Less than 1K followers
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.92 %
-25.39 %
-80.35 %
-78.41 %
-86.50 %
-85.31 %
-95.00 %
-95.09 %
-99.35 %
Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.
Read moreMarket cap
173.01M SEK
Turnover
69.99K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.2.
2026
Annual report '25
29.4.
2026
Interim report Q1'26
7.5.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Medivir presenting at the Redeye Life Science Day 2025
BioStock: Medivir comments on orphan drug designation and progress in partnerships
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
